RxDoctor Payments Data

Kaci Younger

Family · Mason City, IANPI 1306475843

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 271 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 18.6% — the pattern of someone who eats at a lot of different presentations. Among family clinicians in IA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$4,332in general payments, 2019–2025

Across 271 payments — averaging $15.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$807
  • AbbVie$751
  • Boehringer Ingelheim$419
  • Novo Nordisk$395
  • AstraZeneca$370
  • Lilly USA, LLC$325
  • plus $1K from 26 others

What the payments were for

  • Food & beverage$4,332100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,332 in reported general payments places this provider in the 95th percentile of 1,268 family providers in Iowa.

See all family providers in Iowa

Medicare billing

Part B allowed, 2024
$20,235
Medicare patients
74
Services billed
328

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide28$26,873
JardianceEmpagliflozin14$21,393
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$7,567
XareltoRivaroxaban11$6,367
Levothyroxine Sodium67$594
Bupropion Hcl SrBupropion Hcl13$539
Pregabalin17$463
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine11$438
Bupropion Hcl12$432
Famotidine31$426
Duloxetine Hcl22$423
Omeprazole42$418
Losartan Potassium62$405
Potassium Chloride26$394
Diltiazem 24hr Er (Cd)Diltiazem Hcl12$389

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity$325$26,87328 claims
Boehringer IngelheimJardiance$419$21,39314 claims
GSKTrelegy Ellipta$79$7,56711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,268 family providers in Iowa.

Other family in Mason City

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →